Show simple item record

dc.contributor.author Rebec, George V.
dc.contributor.author Miller, Benjamin R.
dc.contributor.author Barton, Scott J.
dc.contributor.author Prieto, Anne L.
dc.contributor.author Sari, Youssef
dc.date.accessioned 2012-03-14T01:58:00Z
dc.date.available 2012-03-14T01:58:00Z
dc.date.issued 2010-07-27
dc.identifier.citation Sari, Y., Prieto, A. L., Barton, S. J., Miller, B. M., Rebec, G. V. (2010). Ceftriaxone-induced up-regulation of GLT1 expression at multiple stages of Huntingtons disease in the R6/2 model. J. Biomed. Sci., 17:62 (1-5). en
dc.identifier.uri http://www.jbiomedsci.com/content/17/1/62 en
dc.identifier.uri http://hdl.handle.net/2022/14265
dc.description.abstract Background: Huntington’s disease (HD) is an inherited neurodegenerative disorder characterized by cortico-striatal dysfunction and loss of glutamate uptake. At 7 weeks of age, R6/2 mice, which model an aggressive form of juvenile HD, show a glutamate-uptake deficit in striatum that can be reversed by treatment with ceftriaxone, a b-lactam antibiotic that increases GLT1 expression. Only at advanced ages (> 11 weeks), however, do R6/2 mice show an actual loss of striatal GLT1. Here, we tested whether ceftriaxone can reverse the decline in GLT1 expression that occurs in older R6/2s. Results: Western blots were used to assess GLT1 expression in both striatum and cerebral cortex in R6/2 and corresponding wild-type (WT) mice at 9 and 13 weeks of age. Mice were euthanized for immunoblotting 24 hr after five consecutive days of once daily injections (ip) of ceftriaxone (200 mg/kg) or saline vehicle. Despite a significant GLT1 reduction in saline-treated R6/2 mice relative to WT at 13, but not 9, weeks of age, ceftriaxone treatment increased cortical and striatal GLT1 expression relative to saline in all tested mice. Conclusions: The ability of ceftriaxone to up-regulate GLT1 in R6/2 mice at an age when GLT1 expression is significantly reduced suggests that the mechanism for increasing GLT1 expression is still functional. Thus, ceftriaxone could be effective in modulating glutamate transmission even in late-stage HD. en
dc.language.iso en_US en
dc.publisher BioMed Central Ltd en
dc.rights © 2010 Sari et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. en
dc.rights.uri http://creativecommons.org/licenses/by/2.0 en
dc.title Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington’s disease en
dc.type Article en


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2010 Sari et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. © 2010 Sari et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Search IUScholarWorks


Advanced Search

Browse

My Account

Statistics